Vega Investment Solutions Takes Position in Boston Scientific Corporation $BSX

Vega Investment Solutions acquired a new position in Boston Scientific Corporation (NYSE:BSX) during the 2nd quarter, HoldingsChannel.com reports. The firm acquired 11,186 shares of the medical equipment provider’s stock, valued at approximately $477,000.

Several other institutional investors have also recently added to or reduced their stakes in BSX. Kelleher Financial Advisors acquired a new position in Boston Scientific during the second quarter worth $25,000. FWL Investment Management LLC acquired a new stake in shares of Boston Scientific in the second quarter valued at $26,000. Swiss RE Ltd. acquired a new stake in shares of Boston Scientific in the fourth quarter valued at $26,000. Garton & Associates Financial Advisors LLC purchased a new stake in shares of Boston Scientific in the 4th quarter valued at $26,000. Finally, Clal Insurance Enterprises Holdings Ltd purchased a new stake in shares of Boston Scientific in the 1st quarter valued at $28,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Trading Down 2.8%

Shares of NYSE:BSX opened at $48.98 on Tuesday. Boston Scientific Corporation has a 52 week low of $42.20 and a 52 week high of $109.50. The company’s 50 day moving average is $46.38 and its two-hundred day moving average is $57.32. The company has a market cap of $70.99 billion, a PE ratio of 19.83, a P/E/G ratio of 1.10 and a beta of 0.56. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $0.03. The business had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same period in the previous year, the company earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities analysts predict that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific declared that its Board of Directors has approved a stock buyback plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its stock is undervalued.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director David C. Habiger purchased 2,100 shares of the firm’s stock in a transaction on Wednesday, August 5th. The stock was bought at an average cost of $47.59 per share, with a total value of $99,939.00. Following the acquisition, the director directly owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. This represents a 13.94% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Michael F. Mahoney acquired 186,240 shares of the stock in a transaction dated Monday, August 3rd. The shares were acquired at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the transaction, the chief executive officer owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This represents a 13.27% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 194,522 shares of company stock worth $9,385,210 over the last ninety days. Corporate insiders own 0.34% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Robert W. Baird set a $56.00 target price on Boston Scientific in a report on Thursday, July 30th. Truist Financial cut their price target on shares of Boston Scientific from $62.00 to $57.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. BTIG Research reduced their price target on shares of Boston Scientific from $65.00 to $60.00 and set a “buy” rating on the stock in a research report on Wednesday, July 29th. Raymond James Financial reissued an “outperform” rating and issued a $57.00 price objective on shares of Boston Scientific in a research note on Thursday, July 30th. Finally, Royal Bank Of Canada dropped their price objective on shares of Boston Scientific from $85.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, July 30th. Twenty-four research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Boston Scientific presently has a consensus rating of “Moderate Buy” and a consensus target price of $71.62.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.